Search

Introduction La syphilis reste un probleme de sante publique dans la plupart des pays occidentaux et le nombre de cas a augmente depuis 2000. La benzathine penicilline G (BPG) est le traitement de reference de la syphilis precoce, mais les ruptures de stock recentes renforcent la necessite de valider des traitements alternatifs. Le but de cette etude etait d’evaluer la presence des marqueurs genomiques de la resistance de Treponema pallidum subs pallidum (TPA) aux macrolides et a la doxycycline en France. Materiel et methodes Des prelevements de lesions genitales, anales, orales et cutanees ont ete obtenus aupres de patients atteints de syphilis precoce ayant consulte dans 9 CeGIDD. Tous les echantillons analyses etaient positifs en nPCR pour tpp47. Les mutations de resistance aux macrolides A2058G et A2059G sur le gene de l’ARN ribosomal 23S et les mutations ponctuelles de resistance a la doxycycline 926–928, 939, 965–967 et 1058 sur le gene de l’ARNr 16S ont ete recherchees par amplification genomique et sequencage. Resultats Cent quarante-six prelevements provenant de 146 patients ont ete collectes entre octobre 2010 et janvier 2017. La majorite etait des hommes (80 %) ; l’âge moyen etait de 39 ans. La part d’hommes ayant des rapports sexuels avec des hommes etait de 80 % et le nombre de seropositifs pour le VIH de 33 %. Les syphilis primaires representaient 63,7 % des echantillons. Nous montrons que 85 % (88/104) des ADN amplifies et sequences possedent la mutation A2058G conferant une resistance aux macrolides. En revanche, pour un taux d’amplification/sequencage du gene de l’ARNr 16S de 87 % (127/146), aucune mutation ponctuelle conferant une resistance a la doxycycline n’a ete detectee. Discussion Nos resultats confirment qu’en France, comme dans d’autres pays occidentaux, la resistance aux macrolides est tres repandue. C’est la raison pour laquelle les macrolides ne peuvent etre recommandes comme traitement alternatif a la BPG. A l’inverse, notre etude confirme l’absence de mutations de resistance de TPA aux cyclines. Ces resultats sont en accord avec les travaux de precedentes etudes asiatique, italienne et espagnole. Bien que n’offrant pas l’avantage d’un traitement minute, l’absence de resistance genomique souligne que la doxycycline peut representer une alternative a la BPG pour le traitement de la syphilis precoce. La surveillance de la sensibilite des souches de TPA aux cyclines doit cependant etre renouvelee du fait de la proposition recente d’utilisation de la doxycycline en prophylaxie post exposition des infections sexuellement transmissibles bacteriennes (PEP) dans le cadre de la prophylaxie pre-exposition de l’infection a VIH (PrEP).

Background Pembrolizumab, a PD-1 inhibitor combined with platinum-based Ctx is standard therapy for eligible pts without a targetable mutation, stage IIIB/IV NSCLC. Currently, there is no data to guide treatment following progression on sequential/concomitant use of platinum-based Ctx and PD-1 inhibitors. Activation of inflammation and elevated baseline c-reactive protein (CRP) levels are associated with a lower response to immunotherapies. Canakinumab is a high-affinity anti-IL-1β monoclonal antibody that showed a significant reduction in the incidence of fatal and nonfatal lung cancer in myocardial infarction pts with increased CRP levels (CANTOS study). Trial design CANOPY-2 (NCT03626545) is a multicenter, phase 3 study evaluating the safety and efficacy of docetaxel ± canakinumab in pts with squamous/non-squamous, stage IIIB-IV NSCLC. This study includes a safety run-in part (part 1 – open-label) to confirm recommended phase 3 regimen (RP3R) to be used in the randomized phase 3 part (part 2 – double-blind, placebo-controlled). Key inclusion criteria: adult pts pretreated with one prior platinum-based Ctx and one prior PD-(L)1 inhibitor therapy for locally advanced or metastatic disease, either together/sequentially and then progressed; ECOG PS 0-1. In part 1, ∼9 pts will be enrolled to have at least 6 evaluable pts and ∼226 pts will be randomized (1:1, stratified by the number of prior lines of therapy and histology) in part 2 to docetaxel ± canakinumab. Primary objectives: to confirm RP3R of canakinumab + docetaxel, as determined by the incidence of dose-limiting toxicity in the first 42 days of administration (part 1) and overall survival (part 2). Secondary objectives: overall response rate, disease control rate, duration of response, time to response, progression-free survival by investigator (RECIST v1.1), safety, PK, immunogenicity of canakinumab, and patient-reported outcomes. Part 1 is completed and part 2 is ongoing after confirming canakinumab 300 mg Q3W as RP3R. Clinical trial identification ACZ885V2301/NCT03626545. Legal entity responsible for the study Novartis. Funding Novartis. Disclosure D. Lim: Advisory / Consultancy: MSD, Novartis, Astra-Zeneca, Boerhinger-Ingelheim; Honoraria (self): MSD, Novartis, Boehringer-Ingelheim. Y. Goto: Speaker Bureau / Expert testimony: AstraZeneca, Eli Lilly, Chugai, Taiho Pharmaceutical, Boehringer Ingelheim, Ono Pharmaceutical, Bristol-Myers Squibb, Pfizer, MSD, Shionogi Pharma, Novartis; Advisory / Consultancy: Eli Lilly, Chugai, Taiho Pharmaceutical, Boehringer Ingelheim, Pfizer, Novartis, AstraZeneca, Glaxo Smith Kline; Research grant / Funding (self): AbbVie, Eli Lilly, Taiho Pharmaceutical, Bristol-Myers Squibb, Ono Pharmaceutical, Daiichi Sankyo, Pfizer, Novartis, Kyorin. B.C. Cho: Honoraria (self): Novartis, Bayer, AstraZeneca, MOGAM Institute, Dong-A ST, Champions Oncology, Janssen, Yuhan, Ono, Dizal Pharma, MSD; Advisory / Consultancy: Novartis, AstraZeneca, Boehringer Ingelheim, Roche, BMS, Ono, Yuhan, Pfizer, Eli Lilly, Janssen, Takeda, MSD; Research grant / Funding (self): Novartis, Bayer, AstraZeneca, MOGAM Institute, Dong-A ST, Champions Oncology, Janssen, Yuhan, Ono, Dizal Pharma, MSD; Shareholder / Stockholder / Stock options: TheraCanVac Inc; Licensing / Royalties: Champions Oncology. H. Kaneda: Honoraria (self): Novartis; Advisory / Consultancy: Novartis. J-H. Kang: Honoraria (self): Roche, AZ, Merck ; Advisory / Consultancy: AZ, MSD, Takeda; Research grant / Funding (self): AZ, Yuhan, CKD, Astellas. S-W. Kim: Advisory / Consultancy: AstraZeneca; Research grant / Funding (self): AstraZeneca, Lilly, Boehringer Ingelheim. C-H. Chiu: Honoraria (self): AstraZeneca, Bristol-Myers Squibb, Merck Sharp & Dohme, Novartis, Ono Pharmaceutical, Pfizer, Roche. J.C-H. Yang: Honoraria (self): Novartis, personal fees from Boehringer Ingelheim, personal fees from Eli Lilly, personal fees from Roche/Genentech, personal fees from Chugai, personal fees from MSD, personal fees from Pfizer, personal fees from Novartis, personal fees from BMS, persona; Advisory / Consultancy: Novartis, personal fees from Boehringer Ingelheim, personal fees from Eli Lilly, personal fees from Bayer, personal fees from Roche/Genentech, personal fees from Astellas, personal fees from MSD, personal fees from Merck Serono, personal fees from Pfizer. W-C. Su: Travel / Accommodation / Expenses: BI, BMS. K. Obyrne: Advisory / Consultancy: Boehringer Ingelheim, Merck Sharpe and Dohme, Eli Lilly, AstraZeneca, Roche, Pfizer, Bristol-Myers Squibb, and Novartis. V. Papadimitrakopoulou: Advisory / Consultancy: Nektar Therapeutics, AstraZeneca, Arrys Therapeutics, Merck, LOXO Oncology, Araxes Pharma, F Hoffman-La Roche, Janssen Research Foundation, Bristol-Myers Squibb, Clovis Oncology, Eli Lilly, Novartis, Takeda, AbbVie, TRM Oncology, Tesaro, Exelixis, Gritsto; Honoraria (self): F Hoffman-La Roche; Research grant / Funding (self): Eli Lilly, Novartis, Merck, AstraZeneca, F Hoffman-La Roche, Nektar Therapeutics, Janssen, Bristol-Myers Squibb, Checkmate, Incyte (to institution). M. Reck: Speaker Bureau / Expert testimony: AbbVie, Amgen, AstraZeneca, BMS, Boehringer Ingelheim, Celgene, Lilly, Merck, MSD, Novartis, Pfizer, Roche; Advisory / Consultancy: AbbVie, Amgen, AstraZeneca, BMS, Boehringer Ingelheim, Celgene, Lilly, Merck, MSD, Novartis, Pfizer, Roche; Honoraria (self): AbbVie, Amgen, AstraZeneca, BMS, Boehringer Ingelheim, Celgene, Lilly, Merck, MSD, Novartis, Pfizer, Roche; Officer / Board of Directors: IASLC BOD, Member of Scientific Committee. I. Malet: Shareholder / Stockholder / Stock options: Novartis; Full / Part-time employment: Novartis. B. Mookerjee: Full / Part-time employment: Novartis; Shareholder / Stockholder / Stock options: Novartis, Glaxo Smith Kine, Incyte, AstraZeneca. Z. Zewen: Full / Part-time employment: Novartis; Shareholder / Stockholder / Stock options: Novartis. L. Paz-Ares Rodriguez: Advisory / Consultancy: Roche, Lilly, Novartis, Pfizer, BMS, MSD, Takeda, AstraZeneca, Boehringer Ingelheim, Bayer, Janssen, Celgene; Honoraria (self): Roche, Lilly, Novartis, Pfizer, BMS, MSD, Amgen, Merck, Sanofi, Takeda, AstraZeneca, Boehringer Ingelheim, Bayer, Janssen, PharmaMar, Celgene.

Two cylindrical interruptions of the SIGMA telescope passive shield act as collimators projecting arc-shaped images on the detector. The field of view (FOV) of these collimators produces significant sidelobes in the telescope sensitivity diagram. The imaging properties of SIGMA exploiting these sidelobes enable spatial analysis of the diffuse galactic continuum in the 35–600 keV energy range by means of model fitting. A model, based on the spatial distribution of atomic and molecular gas of the Galaxy, is considered. The obtained spectrum of the diffuse γ-ray emission is then compared to theoretical predictions of various contributions in which orthopositronium and cosmic-ray electrons are involved.

Background: Dipeptidyl peptidase IV is a transmembrane enzyme widely expressed in many cell types, but also present as a soluble form in biological fluids. Its abnormal activity is sometimes associated with liver disease related pathologies. Objectives: The aim of this study was to evaluate the clinical relevance of changes in serum DPPIV activity in hepatitis C and other viral infections. Study design: DPPIV activity was assessed by using a microplate-based colorimetric assay on serum from 88 subjects: 12 healthy uninfected controls, 10 patients with primary biliary cirrhosis (PBC) as a reference group, 36 HCV-infected patients, and patients suffering from viral infections of different etiologies. Levels of DPPIV activity were compared with: (1) those of other serum biochemical parameters such as alanine aminotransferase (ALT), aspartate aminotransferase (AST) and gamma glutamyl transpeptidase (GGT), and bilirubin concentrations; and (2) criteria representativ eo f liver histological status. Results: Compared with healthy subjects, DPPIV activity was significantly increased during viral infections and in PBC (P B/0.01). In HCV-infected patients, the median activity (interquartile range, IQR), 29.78 IU/l (24.66/35.95), differed significantly (P B/0.05) from that of controls: 21.42 (19.76/24.93). No correlation was observed between DPPIV activity and either ALT, AST, bilirubin, or the stage of liver fibrosis and necroinflammatory activity, although GGT was moderately correlated (r/ 0.58, P B/0.05). Conclusions: Although we confirmed an elevation of serum DPPIV activity in PBC, it seems to be a non-specific phenomenon common to viral infections. The absence of correlation between serum DPPIV and markers of liver disease in HCV-infected patients, suggests that this activity originates not only from the liver, but also from other sources such as peripheral blood cells involved in the control of viral infections. # 2002 Elsevier Science B.V. All rights reserved.

The gamma-ray emission above 250 GeV from the BL Lac object Markarian 421 was observed by the CAT Cherenkov imaging telescope between December, 1996, and June, 2000. In 1998, the source produced a series of small flares, making it the second extragalactic source detected by CAT. The time-averaged differential spectrum has been measured from 0.3 to 5 TeV, which is well fitted with a power law with an index of -2.88+-0.12(stat)+-0.06(syst). In 2000, the source showed an unprecedented activity, with variability time-scales as short as one hour, as for instance observed during the night between 4 and 5 February. The 2000 time-averaged spectrum measured is compatible with that of 1998, but some indication of a spectral curvature is found between 0.3 and 5 TeV. The possibility of TeV spectral hardening during flares is also discussed, and the results are compared to those obtained on the other TeV BL Lac, Markarian 501., Latex2e, 11 pages, 7 figures, accepted for publication in Astronomy & Astrophysics

The CAT Telescope has observed the Blazar Mrk421 since 1996. The light curve for the whole period is presented. For the 2 flaring periods of 1998 and 2000 the energy spectra have been measured. Correlation with X rays data are shown. Finally the variability is presented.

Supernova remnants (SNR) can be broadly classified into two types: plerionic or plasma-filled SNR, like the Crab Nebula, and shell-type SNR, like Cassiopeia A (Cas A). VHE observations of the Crab Nebula and Cas A made with the CAT atmospheric Cherenkov imaging telescope are used to constrain models for production of gamma rays in SNR. For both plerionic and shell-type SNR, these observations serve primarily to impose a limit on the magnetic field in the region where the particles are accelerated.

We have converted the THEMIS solar array (French Pyrenees) into an atmospheric Cherenkov telescope, called CELESTE, sensitive to astrophysical gamma rays above 30 GeV (7×10 24 Hz). In early 1998 the Crab nebula was detected at 80 GeV with a preliminary 18 heliostat setup. The full 40 heliostat array has since been commissioned. The STACEE experiment using the same technique in New Mexico is also analysing their first data. Thus, the window between the EGRET instrument and the Cherenkov imagers has been opened. We describe the CELESTE detector and the data analysis, and discuss the prospects for studying AGN (specifically, blazars) and galactic sources in this energy range.

A new method of shower-image analysis is presented which appears very powerful as applied to those Cherenkov Imaging Telescopes with very high definition imaging capability. It provides hadron rejection on the basis of a single cut on the image shape, and simultaneously determines the energy of the electromagnetic shower and the position of the shower axis with respect to the detector. The source location is also reconstructed for each individual gamma-ray shower, even with one single telescope, so for a point source the hadron rejection can be further improved. As an example, this new method is applied to data from the CAT (Cherenkov Array at Themis) imaging telescope, which has been operational since Autumn, 1996., 22 pages. submitted to Elsevier Preprint

The CELESTE experiment will be an Atmospheric Cherenkov detector designed to bridge the gap in energy sensitivity between current satellite and ground-based gamma-ray telescopes, 20 to 300 GeV. We present test results made at the former solar power plant, Themis, in the French Pyrenees. The tests confirm the viability of using a central tower heliostat array for Cherenkov wavefront sampling., LaTeX2e,30 pages including 14 figures, accepted for publication by Nuclear Instruments & Methods Section A

The CAT (Cherenkov Array at Themis) imaging telescope, equipped with a very-high-definition camera (546 fast phototubes with 0.12 degrees spacing surrounded by 54 larger tubes in two guard rings) started operation in Autumn 1996 on the site of the former solar plant Themis (France). Using the atmospheric Cherenkov technique, it detects and identifies very high energy gamma-rays in the range 250 GeV to a few tens of TeV. The instrument, which has detected three sources (Crab nebula, Mrk 421 and Mrk 501), is described in detail., 24 pages, 15 figures. submitted to Elsevier Preprint

X‐ray binaries form the bulk of hard x‐ray sources, in the 30–300 keV range. More than twenty of them have been detected by SIGMA. Suspected black hole systems seem to be particularly numerous among the sources emitting above 100 keV, and their spectra appear harder than those of neutron star systems. This amounts to a spectral distinction between the two classes of x‐ray binaries. The nature of the companion (high mass or low mass) does not affect this conclusion.

Abstract 4838 Background: Regularly transfused patients including those with MDS and AA inevitably accumulate iron in various tissues, hence the importance of iron chelation to prevent end organ dysfunction. Studies of iron chelation in MDS and AA have mostly used serum ferritin as an efficacy indicator; LIC data, a more direct measure of clinical benefit are limited in these patients. Here, we report results from a 1-year Phase II, multicenter study evaluating the effect of deferasirox (DFX) on LIC in iron-overloaded patients with MDS, AA, and other rare anemias. Methods: Patients aged ≥2 yrs with transfusional iron overload due to low/intermediate (Int-1) risk MDS, AA and other congenital or acquired anemias were enrolled. Patients with thalassemia and SCD were excluded. Patients required a lifetime transfusion history of ≥20 units of packed red blood cells (RBC) or serum ferritin >1000 ng/mL. DFX was administered at a starting dose of 20 mg/kg/day; some patients started on 10 or 30 mg/kg/day based on transfusion requirements and therapeutic goals. Dose adjustments were based on serum ferritin trends and safety parameters. Primary endpoint was absolute change in LIC assessed by R2 MRI (Ferriscan®) from baseline (BL) to 1 year. Secondary objectives included analyses of change in serum ferritin, iron balance and safety. Results: 102 patients (MDS n=42 [41.2%], AA n=29 [28.4%] and other rare anemias n=31 [30.4%]) were enrolled. Median age was 56.5 yrs (range 2–85 yrs). 68 (67%) patients completed 1 year of treatment. Average actual dose (mean ± SD) was 18.5 ± 5.6 mg/kg/day; 64 patients (62.7%) received an average dose of 15– Mean ± SD BL LIC was 24.5 ± 15.6 mg Fe/g dw (n=102); with 23.5% (n=24) and 56.9% (n=58) of patients having LIC >7– Most frequent (≥5%) adverse events (AE) suspected by the investigator to be drug-related were increased blood creatinine (n=19, 18.6%), skin rash (n=9, 8.8%), renal impairment (n=8, 7.8%), diarrhea (n=7, 6.9%), nausea (n=7, 6.9%), abdominal pain (n=6, 5.9%) and constipation (n=6, 5.9%). 14 severe AEs suspected to be drug-related were reported in 10 patients, the most frequent (≥2) being rash (n=2) and hypersensitivity (n=2). Five patients died (general physical health deterioration [n=2], cerebellar hemorrhage, disseminated intravascular coagulation and traumatic hemorrhage [n=1 for each]); none were considered drug-related. Cataract was reported in 4 patients (3.9%); 1 suspected as drug-related. Auditory AEs were reported in 7 patients; aggravated deafness (n=1) and tinnitus (n=1) suspected to be drug-related. Of 19 patients treated with concomitant cyclosporine (CyA), 11 (57.9%) had increases in serum creatinine (>33% above BL and >ULN at 2 consecutive visits) compared with 18 of the remaining 83 patients (21.7%) who did not receive CyA. Conclusions: A large proportion of patients in this study with transfusion-dependent Low/Int-1 risk MDS, AA and other rare anemias had severe liver iron overload (LIC ≥15 mg Fe/g dw). 1 year of DFX treatment significantly reduced iron burden, as assessed by both LIC and serum ferritin; with iron excretion 2–3 times higher than iron intake. Furthermore, change in LIC correlated with change in serum ferritin and ALT, a clinically relevant indicator of liver function. Overall the DFX safety profile was consistent with that from previous studies. Renal function in patients receiving DFX and concomitant CyA should be closely monitored as previously noted in the EPIC trial. Disclosures: Kohgo: Kyorin Pharma: Research Funding; Sapporo Brewery: Research Funding; Asahikasei Kurare Medical: Research Funding; Chugai Roche: Research Funding; Novartis: Research Funding, Speakers Bureau. Sanz:Novartis: Speakers Bureau. Helou:Novartis: Employment. Habr:Novartis: Employment. Malet:Novartis: Employment. Glaser:Novartis: Employment. Wiktor-Jedrzejczak:Novartis: Honoraria, Research Funding; Janssen-Cilag: Honoraria.

Des agents de sutface et des insecticides sont souvent appliqués principalement a la laine. Ils sont très importants dans les effluents du procedé antimite. On montre les effets de ceux composés vis-à-vis de trois especes de microalgues en differentes conditions de lumiere. On determine la toxicité, les variations dans les niveaux des pigments algales, et le comportement statistique de la réponse despopulations choisies.

The HEXAGONE balloon‐borne spectrometer has flown on 22 May 1989. HEXAGONE is a high resolution gamma‐ray spectrometer and consists of an array of twelve cooled germanium detectors. One of the observed targets was the Galactic Center and its vicinity (field of view 19° at 511 keV) and it was seen during 6.3 hours. The 511 keV annihilation line was observed with a flux of (8.88±2.67)×10−4 γcm−2 s−1, a width 1.09+1.38, −1.09 keV and its centroid at 511.54±0.38 keV. The results are consistent with an upper limit of 8.3×104 K for the temperature of the annihilation medium of the positrons.

We report an observation of the galactic 1809 keV gamma‐ray line produced by radioactive 26Al in the interstellar medium. The measurement was performed with our high resolution germanium spectrometer HEXAGONE on a balloon flight in May 1989 from Alice Springs, Australia. Our differential spectrum of the Galactic Center region shows a narrow line at 1809 keV corresponding to a flux of (1.9 +/− 0.9) ⋅ 10−4 photons ⋅ cm−2 s−1 assuming a source at the Galactic Center. We discuss the available observations of the 1809 keV line in the context of models that have been proposed for the origin of the galactic 26Al.

Methodes Evaluation prospective des patients en echec therapeutique aux 3 classes d’antiretroviraux, ayant debute RAL entre le 28 novembre 2006 et le 30 septembre 2007. Donnees recueillies CD4-CV a J0-M1-3-6-9-12, genotype de resistance du VIH avant J0 puis en cas d’echec virologique. Definition du succes virologique : CV VIH Resultats 51 patients inclus entre le 28/11/06 et le 30/09/07. Anteriorites ARV: enfuvirtide (57 %), darunavir (68 %), etravirine (37 %), foscarnet (12 %). TO a J0 : enfuvirtide (35 %), darunavir (84 %), etravirine (74 %), atazanavir (29 %), foscarnet (6 %). Caracteristiques a J0 (medianes) : CV = 4,18 log [2,53 ; 5,86], CD4 = 169/mm 3 [1 ; 833], mutations de resistance NRTI = 7 [1 ; 10], NNRTI = 1 [0 ; 4], I p = 13 [8 ; 20]. Tous les patients ont ete suivis jusqu’a M3 ; 31 jusqu’a M6, 14 jusqu’a M9, 2 jusqu’a M12. 34/51 patients (67 %) etaient en succes virologique a M3, 19/31 (61 %) a M6. Parmi les 17/51 patients (33 %) avec CV > 40 cp/ml a M3, 2 groupes sont distingues : – Groupe 1 = Viremie jamais indetectable ; – Groupe 2 = Rebond virologique. Groupe 1 Groupe 2 40 8 4 CV > 400 cp/ml (Npts) 4 1 Duree moyenne de suivi (mois) 5,3 6,5 Un sequencage genomique du VIH a ete realise pour les 17 patients avec viremie persistante a M3 ou plus. Des mutations de resistance au RAL ont ete retrouvees sur 4/17 genomes viraux : G140S + Q148H (2 cas), N155H (2 cas). Ces mutations ont ete observees uniquement chez les patients avec CV > 400cp/ml (4/5). Conclusion Taux eleve de succes virologiques chez ces patients en multi echec (67 %). – Faible taux d’emergence de mutations de resistance au RAL, observees chez les patients avec CV > 400 cp/ml. – L’etude de facteurs predictifs d’echec virologique incluant concentrations plasmatiques de RAL et profils genotypiques a J0 est en cours.

A positive detection of the 0.511-MeV annihilation line from the inner Galaxy is reported. The observation has been performed with the Figaro II experiment (field of view 77 deg) during a balloon flight from Charleville, Australia on November 25-26, 1988. Assuming a single point source the flux is 0.00224 + or - 0.00041 photons/sq cm sec, while for an extended, disk source the differential flux is 0.00191 + or - 0.00032 photons/sq cm sec rad at the Galactic center. 14 refs.

On 1989 May 22, the High Energy X-ray and Gamma-ray Observatory for Nuclear Emissions, a balloon-borne high-resolution germanium spectrometer with an 18-deg FOV, observed the Galactic Center (GC) from 25 to 2500 keV. The GC photon spectrum is obtained from the count spectrum by a model-independent method which accounts for the effects of passive material in the instrument and scattering in the atmosphere. Besides a positron annihilation line with a flux of (10.0 +/- 2.4) x 10 exp -4 photons/sq cm s and a full width at half-maximum (FWHM) of (2.9 + 1.0, -1.1) keV, the spectrum shows a peak centered at (163.7 +/- 3.4) keV with a flux of (1.55 +/- 0.47) x 10 exp -3 photons/sq cm s and a FWHM of (24.4 +/- 9.2) keV. The energy range 450-507 keV shows no positronium continuum associated with the annihilation line, with a 2-sigma upper limit of 0.90 on the positronium fraction. The 164 keV feature is interpreted as Compton backscatter of broadened and redshifted annihilation radiation, possibly from the source 1E 1740.7-2942.

We present here an analysis of the profiles and intensities of the 511 keV annihilation line observed in the direction of the Galactic center by high energy resolution detectors. We first investigate the HEXAGONE 1989 May data, where the point source was in a rather low state. We find that a warm medium (temperature of 8000 K) can describe the annihilation of the positrons from the diffuse component of the line. We compare these results with the Bell/Sandia 1977, and GRIS 1988 October flights during high states of the central source, and we then show that the discrepancy in the line shape and width between these two sets of data is explained if the time-variable component of the line coming form the annihilation of the positrons emitted by the central source annihilates in a cold medium (temperature around 80 K)

[This corrects the article DOI: 10.3389/fimmu.2021.761250.]., (Copyright © 2023 Vanhove, Marot, So, Gaborit, Evanno, Malet, Lafrogne, Mevel, Ciron, Royer, Lheriteau, Raffi, Bruzzone, Mok, Duvaux, Marcelin and Calvez.)